AMLX
NASDAQAmylyx Pharmaceuticals Inc.
News · 26 weeks54-57%
2025-12-072026-05-31
Mix1990d
- Other7(37%)
- Insider6(32%)
- SEC Filings5(26%)
- Earnings1(5%)
Latest news
25 items- INSIDERDirector Firestone Karen bought $51,338 worth of shares (3,800 units at $13.51), increasing direct ownership by 6% to 66,900 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- PRAmylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical InvestigationPeer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic beta cell function, glycemic control, vision, and overall symptom burden AMX0035 was generally well-tolerated, consistent with previously presented safety data The Company continues to work with the FDA on a Phase 3 trial in Wolfram syndrome Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an
- SECSEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: Bank of America's 2026 Health Care Conference: Fireside Chat on Wednesday, May 13, 2026, at 1:40 p.m. PT in Las Vegas, Nevada Goldman Sachs 47th Annual Global Healthcare Conference: Fireside Chat on Wednesday, June 10, 2026, at 10:40 a.m. ET in Miami, Florida A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90
- PRAmylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric HypoglycemiaThe Expanded Access Program allows eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery access to avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor antagonist Avexitide is being evaluated in the pivotal Phase 3 LUCIDITY clinical trial, with topline data readout anticipated in Q3 2026 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. The EAP a
- PRAmylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyx's senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presen
- SECSEC Form DEFA14A filed by Amylyx Pharmaceuticals Inc.DEFA14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECSEC Form DEF 14A filed by Amylyx Pharmaceuticals Inc.DEF 14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric HypoglycemiaLast participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on track; anticipated in Q3 2026 LUCIDITY is evaluating the FDA-agreed-upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the last participant has been randomized and dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with U.S. Food and Drug Administration (FDA) Breakthrough Therapy De
- INSIDERChief Financial Officer Frates James M was granted 95,990 shares, increasing direct ownership by 58% to 261,628 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina was granted 74,660 shares, increasing direct ownership by 56% to 209,090 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B was granted 248,865 shares, increasing direct ownership by 7% to 3,583,548 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. was granted 248,865 shares, increasing direct ownership by 7% to 3,583,481 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L was granted 95,990 shares, increasing direct ownership by 57% to 265,285 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. sold $423,760 worth of shares (29,282 units at $14.47), decreasing direct ownership by 0.87% to 3,334,616 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B sold $424,120 worth of shares (29,282 units at $14.48), decreasing direct ownership by 0.87% to 3,334,683 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Financial Officer Frates James M sold $114,851 worth of shares (7,909 units at $14.52), decreasing direct ownership by 5% to 165,638 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L sold $94,205 worth of shares (6,461 units at $14.58), decreasing direct ownership by 4% to 169,295 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina sold $99,378 worth of shares (6,844 units at $14.52), decreasing direct ownership by 5% to 134,430 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECSEC Form S-8 filed by Amylyx Pharmaceuticals Inc.S-8 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
AMLX FAQ
7 questionsWhat does Amylyx Pharmaceuticals Inc. do?
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Where does AMLX stock trade?
Amylyx Pharmaceuticals Inc. (AMLX) is listed on NASDAQ.What sector and industry is AMLX in?
Amylyx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Amylyx Pharmaceuticals Inc. go public?
Amylyx Pharmaceuticals Inc. (AMLX) completed its IPO in 2022.What are analysts saying about AMLX?
Amylyx Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $2100.00 price target on 2026-03-03. Recent price targets range from $700.00 to $2100.00.What companies are similar to AMLX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AMLX side-by-side with any of them on Quantisnow.How can I track AMLX on Quantisnow?
Quantisnow aggregates Amylyx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMLX to receive live email and push alerts on every new disclosure.